The experience of Biosimilar Medicines in Oncology - European Medical Journal

The experience of Biosimilar Medicines in Oncology

Tune in to this webinar, which takes a retrospective look at the use of monoclonal antibody biosimilars in the treatment of breast cancer. In this upcoming roundtable discussion, the experts will consider experiences with biosimilar products for the treatment of cancer and the likely future uptake of biosimilars. Discussion will focus on:
  • a brief background on biosimilars within oncology;
  • experiences and perspectives of use, including barriers and hurdles;
  • reflections of the economic impact; and
  • expectations and needs for the future.


Molly Billstein Leber is the Manager of Medication Policy and Formulary Management for the Yale New Haven System, Connecticut, USA. Leber is active at both the state and national level. She has served as a board member for the Connecticut Society of Health System Pharmacists (CSHP), where she received the Paul Pierpaoli Award.

Giuseppe Curigliano is Full Professor of Medical Oncology at the University of Milano and Head of the Clinical Division of Early Drug Development at the European Institute of Oncology (IEO), Milan, Italy. He serves as a member of the Italian Higher Health Council and serves the European Society for Medical Oncology (ESMO) as Chair of the Clinical Practice Guidelines Committee.

This was funded by an educational grant from Pfizer, who has no input to the creation of this educational webinar

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally